Spectrum Gets Exclusive License for Lucanthone in Phase II Trials

Spectrum Pharmaceuticals has acquired worldwide exclusive rights to a lucanthone from Robert Bases, the inventor of a method of treating cancer of the central nervous system through the administration of lucanthone and radiation.

Lucanthone is currently in Phase II clinical trials at Montefiore Medical Center. Financial terms were not disclosed.